Anticancer Drug-induced Liver Injury

With the recent advances in the field of medical oncology and the development of new exciting domain of immunotherapy, the longevity of patients with various cancers has increased. With rise in survival of patients with cancer and increasing number of patients undergoing cancer chemotherapy and immunotherapy, the prevalence of drug-induced liver injury (DILI) is increasing as well. Anticancer DILI (AC-DILI) is much more common than previously thought of and can be difficult to diagnose and manage as well. AC-DILI is usually a diagnosis of exclusion, and management includes nonspecific hepatoprotective agents and modification in chemotherapy regimen as per the severity of liver injury. This overall affects the prognosis of the patient as well. We hereby present a comprehensive review about AC-DILI. We discuss upon the types of liver injury and algorithmic approach to diagnose and manage AC-DILI. We also highlight upon immunotherapy-induced liver injury. AC-DILI is a relevant topic for physicians, medical oncologists, as well as hepatologists who are frequently encountering patients having this clinical condition.